Rapport Therapeutics (RAPP) Cash from Operations (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Cash from Operations data on record, last reported at 13061000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations rose 35.46% to 13061000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 80297000.0, a 19.05% decrease, with the full-year FY2025 number at 87473000.0, down 34.93% from a year prior.
- Cash from Operations reached 13061000.0 in Q1 2026 per RAPP's latest filing, up from 24701000.0 in the prior quarter.
- Over the last five years, Cash from Operations for RAPP hit a ceiling of 5424000.0 in Q3 2023 and a floor of 25070000.0 in Q2 2025.
- A 4-year average of 16467545.45 and a median of 16415000.0 in 2024 define the central range for Cash from Operations.
- Peak YoY movement for Cash from Operations: crashed 202.64% in 2024, then soared 35.46% in 2026.
- Tracing RAPP's Cash from Operations over 4 years: stood at 10357000.0 in 2023, then plummeted by 39.48% to 14446000.0 in 2024, then tumbled by 70.99% to 24701000.0 in 2025, then skyrocketed by 47.12% to 13061000.0 in 2026.
- Business Quant data shows Cash from Operations for RAPP at 13061000.0 in Q1 2026, 24701000.0 in Q4 2025, and 17465000.0 in Q3 2025.